Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Lung; Node
Interventions: RAB via the Monarch platform, RAB via the ION platform; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastrointestinal Neoplasms
Interventions: Risvutatug Rezetecan; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Los Alamitos, California • Los Angeles, California • Santa Monica, California + 8 more

Conditions: Solid Tumor
Interventions: AT-1965 Liposome Injection; Drug
Lead sponsor: Alyssum Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Bakersfield, California • El Segundo, California + 5 more

Conditions: Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult
Interventions: Motion Perception Task, Sine Wave Speech Task, Volatility Task, Choice Probabilistic Reversal Task, Kamin Blocking Task, Minnesota Trust Game, Dynamic Trust Game; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 59 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • St Louis, Missouri

Conditions: Depression
Interventions: Rejection and Acceptance Feedback; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Generalized Myasthenia Gravis (gMG)
Interventions: Zilucoplan®; Drug
Lead sponsor: Miriam Freimer; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Tampa, Florida • Kansas City, Kansas • Columbus, Ohio

Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8
Interventions: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Positron Emission Tomography, Tumor Resection; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Orange, California + 8 more

Conditions: Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Pancreatic Exocrine Neoplasm, Stage IVB Prostate Cancer American Joint Committee on Cancer v8, Triple-Negative Breast Carcinoma
Interventions: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Rochester, New York

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 33
States / cities: Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 29 more

Conditions: Breast Cancer
Interventions: Navigation, TEAM; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 40 Years to 74 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chinle, Arizona

Conditions: ACL Surgery, Pain Management
Interventions: Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • Orange, California + 13 more

Conditions: Post Operative Pain
Interventions: AtriCure Cryo Nerve Block (cryoNB) Device Family; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2040
U.S. locations: 7
States / cities: Jacksonville, Florida • Orlando, Florida • Annapolis, Maryland + 4 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions: Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection; Other · Radiation · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more

Conditions: Symptomatic Severe Native Aortic Stenosis, Aortic Stenosis
Interventions: TAVR Device, Siegel TAVR Device; Device
Lead sponsor: MiRus; Industry
Eligibility: 18 Years and older
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Disease
Interventions: Cogmed+; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 16 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: TRE plus SOC, SOC, TRE; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: Voyager DSLT; Device
Lead sponsor: The Eye Institute of West Florida; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Largo, Florida

Conditions: Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions: MODI Algorithm; Device
Lead sponsor: DreaMed Diabetes; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more

Conditions: Lymphoma, Malignant Solid Neoplasm
Interventions: Best Practice, Comprehensive Geriatric Assessment, Educational Intervention, Exercise Intervention, Questionnaire Administration, Tailored Intervention; Other · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 45
States / cities: Tuscaloosa, Alabama • Fremont, California • San Francisco, California + 34 more

Conditions: Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis
Interventions: Coronary computed tomography angiography; Diagnostic Test
Lead sponsor: HeartFlow, Inc.; Industry
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Greenwood Village, Colorado

Conditions: Breast Neoplasms
Interventions: Imlunestrant, Goserelin, Tamoxifen 20 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 37
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 29 more

Conditions: Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
Interventions: Tirzepatide, Standard medical treatment; Drug · Other
Lead sponsor: Alaa Sada; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial)

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3

Teen Brain Online II: Understanding How Social Media Affects the Teen Brain

Zilucoplan for Severe gMG Exacerbations

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Access to Genetic Testing in Underserved Patients With Cancer

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Community-led Navigation to Address Disparities in Mammography Among Native American Women

Efficacy of Methylprednisolone for Pain Control After ACL Repair

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

DSLT for Reducing Medication in Glaucoma

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

Using CTA Measures to Define Cardiac Risk In NFL Alumni

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion